Key facts
- Laguna Bio’s last known valuation is $32.5M (Nov 2024).
- It has raised $11.7M; the latest was Seed Round in Sep 2025.
- Notable investors include SOSV, IndieBio, University of California, The Venture Collective, Astor Management — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Laguna Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Laguna Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Laguna Bio
Developer of a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company specializes in providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug, enabling patients to survive a deadly disease like cancer.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 7
- Website
- lagunabio.com/
- Ownership
- Privately Held (backing)
Laguna Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Laguna Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Laguna Bio in its N-PORT filings yet. We sweep new filings monthly.